

Jason Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7338021/publications.pdf>

Version: 2024-02-01

31
papers

857
citations

840776

11
h-index

642732

23
g-index

31
all docs

31
docs citations

31
times ranked

1945
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
2	Temporal Trends in the Treatment of Early- and Advanced-Stage Laryngeal Cancer in the United States, 1985-2007. JAMA Otolaryngology, 2011, 137, 1017.	1.2	104
3	Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities. Hearing Research, 2012, 288, 67-76.	2.0	101
4	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
5	Temporal trends in oropharyngeal cancer treatment and survival: 1998â€“2009. Laryngoscope, 2014, 124, 131-138.	2.0	70
6	Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. , 2020, 8, e000319.		67
7	<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
8	Pembrolizumab in men with heavily treated metastatic castrateâ€“resistant prostate cancer. Cancer Medicine, 2019, 8, 4644-4655.	2.8	55
9	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e513-e521.	1.9	31
10	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 473-485.	1.8	24
11	Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e494-e501.	3.6	23
12	The Impact of Comorbidity on Treatment (Chemoradiation and Laryngectomy) of Advanced, Nondistant Metastatic Laryngeal Cancer. JAMA Otolaryngology, 2012, 138, 1120.	1.2	19
13	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 510-518.	1.6	18
14	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 813.e1-813.e9.	1.6	16
15	Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. Journal of Gastrointestinal Cancer, 2015, 46, 166-169.	1.3	14
16	Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with ¹³¹ I-MIBG. Journal of Nuclear Medicine, 2018, 59, 1708-1713.	5.0	12
17	Clinical applications of liquid biopsies in gastrointestinal oncology. Journal of Gastrointestinal Oncology, 2016, 7, 675-686.	1.4	10
18	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncolimmunology, 2020, 9, 1773200.	4.6	10

#	ARTICLE	IF	CITATIONS
19	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1137-e1141.	1.9	8
20	A role for the androgen receptor in the treatment of male breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 358-363.	4.4	5
21	Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians. <i>Journal of Cancer Education</i> , 2015, 30, 774-778.	1.3	4
22	A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e672-e677.	1.9	4
23	Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16079-e16079.	1.6	3
24	Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3007-3007.	1.6	3
25	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	1.9	1
26	Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2595-2595.	1.6	1
27	Comparison of Caucasian and African-American DNA repair alterations in men with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 199-199.	1.6	1
28	Immune checkpoint inhibitor response in tumors with LRP1B variants.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14291-e14291.	1.6	0
29	Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e14259-e14259.	1.6	0
30	Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5062-5062.	1.6	0
31	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5568-5568.	1.6	0